Global health reciprocal innovation: ethical, legal and regulatory considerations.

Autor:	Rid A; Department of Bioethics, The Clinical Center & Department of International Science Policy, Planning and Evaluation, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, USA annette.rid@nih.gov., Aguilera B; Faculty of Medicine and Science, Universidad San Sebastián, Santiago, Chile., Banda C; School of Law, University of Malawi, Zomba, Malawi., Divi R; Methods and Technologies Branch, Epidemiology and Genomics Research Program, National Cancer Institute, Bethesda, Maryland, USA., Harris M; Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK., Kim A; School of Nursing, University of Maryland Baltimore, Baltimore, Maryland, USA., Ossandon M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA., Zervos J; The Global Health Initiative, Henry Ford Health, Detroit, Michigan, USA., Rowthorn V; Graduate School, Umiversity of Maryland Baltimore, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	BMJ global health [BMJ Glob Health] 2024 May 30; Vol. 8 (Suppl 7). Date of Electronic Publication: 2024 May 30.
DOI:	10.1136/bmjgh-2023-014693
Abstrakt:	Global health reciprocal innovation (GHRI) is a recent and more formalised approach to conducting research that recognises and develops innovations (eg, medicines, devices, methodologies) from low- and middle-income countries (LMICs). At present, studies using GHRI most commonly adapt innovations from LMICs for use in high-income countries (HICs), although some develop innovations in LMICs and HICs. In this paper, we propose that GHRI implicitly makes two ethical commitments: (1) to promote health innovations from LMICs, especially in HICs, and (2) to conduct studies on health innovations from LMICs in equitable partnerships between investigators in LMICs and HICs. We argue that these commitments take a significant step towards a more equal global health research enterprise while helping to ensure that populations and investigators in LMICs receive equitable benefits from studies using GHRI. However, studies using GHRI can raise potential ethical concerns and face legal and regulatory barriers. We propose ethical, legal and regulatory considerations to help address these concerns and barriers. We hope our recommendations will allow GHRI to move the global health research enterprise forward into an era where all people are treated equally as knowers and learners, while populations in both LMICs and HICs benefit equitably from studies using GHRI. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu